Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Alsalim W et al
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Our injectable format allows for easy and convenient integration of GLP-1 into your health regimen
Acesulfame-K (Ace-K) Aspartame Banned substances Benzoic acid Butylated hydroxyanisole (BHA) Butylated hydroxytoluene (BHT) Bisphenol A (BPA) Carmine (natural red 4) Cyclamates Eggs Ephedra sinica (Ma Huang) Erythritol Ethyl vanillin Ethylene oxide (ETO) FD&C numbered color pigments Gluten Glycols (propylene glycol) High fructose corn syrup (HFCS) Hydrogenated oils (partially hydrogenated oil, trans-fats) Irradiation Peanuts Polyethylene glycol (PEGs) Propyl gallate Saccharin Sodium benzoate Stearates (stearic acid, magnesium stearate) Sucralose Sulfites (potassium bisulfite, sodium sulfite) Synthetic Vanillin Tertiary buthylhydroquinone (TBHQ) Titanium dioxide *These statements have not been evaluated by the Food and Drug Administration
US$ 22.32
US$ 29.15
US$ 29.68
US$ 20.05
